Abstract
Dendritic cells (DCs) have been used to treat cancer for many years and are now being used as immunomodulatory agents to treat auto immune diseases. This issue of Immunotherapy highlights advances in these fields. Interest has been growing rapidly in immuno therapy of cancer. The range of types of immuno therapy being tested in clini cal trials is growing and their effectiveness is improving [1]. The use of leukocyte reduction therapy prior to the administration of tumor infiltrating lymphocytes to patients with mela noma has improved clinical response rates [2] and improvements in the methods used for the culture and expansion of tumor infiltrating lymphocytes have made tumor infiltrating lymphocyte therapy more practical and widely available [3]. T cells are being genetically engi neered to express chimeric antigen receptors and the adoptive transfer of T cells expressing chimeric antigen receptors specific for CD19 antigen has, in preliminary studies, been found to be effective in inducing clinical responses in patients with B cell lymphomas and leukemias [4]. DC vaccines represent another promising immune therapy for cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
